作者
Stephen D Wiviott, Dietmar Trenk, Andrew L Frelinger, Michelle O’Donoghue, Franz-Josef Neumann, Alan D Michelson, Dominick J Angiolillo, Hanoch Hod, Gilles Montalescot, Debra L Miller, Joseph A Jakubowski, Richard Cairns, Sabina A Murphy, Carolyn H McCabe, Elliott M Antman, Eugene Braunwald
发表日期
2007/12/18
期刊
Circulation
卷号
116
期号
25
页码范围
2923-2932
出版商
Lippincott Williams & Wilkins
简介
Background— The increasing use of higher-than-approved doses of clopidogrel in clinical practice is based in part on the desire for greater levels of inhibition of platelet aggregation (IPA). Prasugrel is a new thienopyridine that is more potent than standard-dose clopidogrel in healthy subjects and patients with stable coronary artery disease. The relative antiplatelet effects of prasugrel versus high-dose clopidogrel in percutaneous coronary intervention patients are unknown.
Methods and Results— Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation–Thrombolysis in Myocardial Infarction 44 (PRINCIPLE-TIMI 44) was a randomized, double-blind, 2-phase crossover study of prasugrel compared with high-dose clopidogrel in patients undergoing cardiac catheterization for planned percutaneous coronary intervention. The primary end point of the loading-dose phase …
引用总数
学术搜索中的文章
SD Wiviott, D Trenk, AL Frelinger, M O'Donoghue… - Circulation, 2007
SD Wiviott, E Braunwald, DJ Angiolillo, S Meisel… - Circulation, 2008